<DOC>
	<DOCNO>NCT00214240</DOCNO>
	<brief_summary>This pilot study ass whether use CytoGam® combination ganciclovir effective reduce CMV viral load time , compare standard treatment IV ganciclovir . Serial blood sample draw measure amount CMV viral load weekly , subject receive treatment ganciclovir , ganciclovir + CytoGam® . Additional CMV viral load blood sampling ( CMV DNA capture qualitative testing ) occur weekly thereafter subject 8 week time CMV diagnosis CMV infection longer detectable , whichever long duration .</brief_summary>
	<brief_title>The Impact Cytogam® Time Viral Load Reduction Kidney Kidney/Pancreas Transplant Recipients With Clinical CMV Disease</brief_title>
	<detailed_description />
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Renal renal/pancreas transplant patient diagnose symptomatic CMV infection receive 48 hrs therapy prior study enrollment serum creatinine &lt; 2.2 time enrollment prior use CMV IgG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>